Skip Navigation
Search Menu
News and Publications

In This Section      
Print This Page

Novel Gene Therapy Experiment Offers Hope For People with Certain Hearing Loss and Dizziness Disorder - 03/23/2017

Novel Gene Therapy Experiment Offers Hope For People with Certain Hearing Loss and Dizziness Disorder

Release Date: March 23, 2017
Whirlin
This image shows stereocilia bundles on inner hair cells from whirler mice after whirlin gene therapy. These hair-like protrusions allow sensory hair cells to detect sound and motion. The whirler mutant mouse has very short stereocilia bundles. After whirlin gene therapy, the stereocilia bundles are increased to normal length (red) and whirlin expression is restored (green).
Credit: Johns Hopkins Medicine

In a first-of-its-kind study published in the March 1, 2017 edition of Molecular Therapy, researchers from the National Institute on Deafness and Other Communication Disorders (NIDCD) and Johns Hopkins University School of Medicine showed that gene therapy was able to restore balance and hearing in genetically modified mice that mimic Usher Syndrome, a genetic condition in humans characterized by partial or total hearing loss, dizziness, and vision loss that worsens over time. The hearing loss and dizziness is caused by abnormalities of the inner ear.

Dizziness and hearing loss are among the most common disabilities affecting humans and can be severe and debilitating. According to the National Health and Nutrition Examination Survey, more than 35% of U.S. adults aged 40 years and older have some degree of balance dysfunction, a major cause of falls in the elderly. According to the Centers for Disease Control, approximately one in three people in the United States between the ages of 65 and 74 has hearing loss, and nearly half of those older than 75 have difficulty hearing. Men are more likely to experience hearing loss than women.  

Primary investigator Wade Chien, M.D., a neurootologist and associate professor with the Johns Hopkins Otolaryngology-Head and Neck Surgery team who also practices at the Johns Hopkins Healthcare and Surgery Center in Suburban Hospital in Bethesda, MD., and his team administered gene therapy to the inner ears of genetically modified mice carrying a mutation in a gene which is associated Usher syndrome. These mutant mice are deaf and have significant balance problems from birth. After gene therapy administration, the balance function of the mutant mice was completely restored. In addition, these mutant also had improvement in hearing. This study was one of the first to show that gene therapy can be used to improve hearing and balance functions in a mouse model of hereditary hearing loss. This study was funded by the NIDCD intramural research program.

“Inner ear gene therapy offers tremendous potential as a new way to help patients with hearing loss and dizziness,” Chien said.  

While the positive results are striking the researchers caution that the results are preliminary and will require additional research in humans to demonstrate fully their utility in treating humans. However, they are optimistic that their data indicate that inner ear gene therapy hold promise for treating a variety of human inherited vestibular and hearing disorders, including Usher syndrome.

His work was supported by funds from the NIH NIDCD Division of Intramural Research ( DC000082-02 to W.W.C., DC000079-03 to L.L.C., DC000048-19 to T.B.F., DC000080 to T.S.F., and DC000060-13 to A.J.G.) and from the Nebraska Tobacco Settlement Biomedical Research Development Fund (to S.M.J.).

For the Media

Contacts:

202-660-6707
gstephe1@jhmi.edu
410-502-9410
vmcmain1@jhmi.edu
 
 
Downloads:

The image that accompanies this news release is available for download.

We are providing it with the understanding that it will be used only to help illustrate the story in the corresponding news release. Please use the credit information provided on this page. If there is anything else you need, please email us at JHMedia@jhmi.edu. Thank you.

View Files